TY - JOUR
T1 - LncRNAs as Regulators of Atherosclerotic Plaque Stability
AU - Petkovic, Aleksa
AU - Erceg, Sanja
AU - Munjas, Jelena
AU - Ninic, Ana
AU - Vladimirov, Sandra
AU - Davidovic, Aleksandar
AU - Vukmirovic, Luka
AU - Milanov, Marko
AU - Cvijanovic, Dane
AU - Mitic, Tijana
AU - Sopic, Miron
N1 - Funding Information:
A.P. is funded European Union (HORIZON-MSCA-2021-SE-01-01—MSCA Staff Exchanges 2021 CardioSCOPE 101086397; S.E. is funded the Ministry of Education, Science and Technological Development, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-47/2023-01/200161, European Union (HORIZON-MSCA-2021-SE-01-01—MSCA Staff Exchanges 2021 CardioSCOPE 101086397); J.M. is funded the Ministry of Education, Science and Technological Development, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-47/2023-01/200161, Science Fund of the Republic of Serbia (HI-MOM project, 7741659), European Union (HORIZON-MSCA-2021-SE-01-01—MSCA Staff Exchanges 2021 CardioSCOPE 101086397); A.N. is funded the Ministry of Education, Science and Technological Development, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-47/2023-01/200161, European Union (HORIZON-MSCA-2021-SE-01-01—MSCA Staff Exchanges 2021 CardioSCOPE 101086397); S.V. is funded the Ministry of Education, Science and Technological Development, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-47/2023-01/200161, Science Fund of the Republic of Serbia (HI-MOM project, 7741659), European Union (HORIZON-MSCA-2021-SE-01-01—MSCA Staff Exchanges 2021 CardioSCOPE 101086397); T.M. is supported by the British Heart Foundation (BHF) Career Re-entry Fellowship (FS/16/38/32351); S.M. is funded the Ministry of Education, Science and Technological Development, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-47/2023-01/200161, European Union (HORIZON-MSCA-2021-SE-01-01—MSCA Staff Exchanges 2021 CardioSCOPE 101086397, HORIZON-MSCA-2021-PF- MAACS 101064175), European Union AtheroNET COST Action CA21153.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/7/12
Y1 - 2023/7/12
N2 - Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.
AB - Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.
KW - atherosclerosis
KW - long non-coding RNAs
KW - plaque stability
UR - http://www.scopus.com/inward/record.url?scp=85165980661&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/37508497
U2 - 10.3390/cells12141832
DO - 10.3390/cells12141832
M3 - Review article
C2 - 37508497
AN - SCOPUS:85165980661
SN - 2073-4409
VL - 12
JO - Cells
JF - Cells
IS - 14
M1 - 1832
ER -